Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) Other Operating Expenses (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed Other Operating Expenses for 5 consecutive years, with $1.3 million as the latest value for Q2 2025.

  • For Q2 2025, Other Operating Expenses changed N/A year-over-year to $1.3 million; the TTM value through Sep 2025 reached $1.3 million, changed N/A, while the annual FY2023 figure was $3.3 million, N/A changed from the prior year.
  • Other Operating Expenses hit $1.3 million in Q2 2025 for Cyclerion Therapeutics, down from $3.3 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $3.3 million in Q3 2023 and bottomed at -$881000.0 in Q2 2021.
  • Average Other Operating Expenses over 3 years is $1.2 million, with a median of $1.3 million recorded in 2025.